GENERATION BIO CO (GBIO)
US37148K1007 - Common Stock
Generation Bio Announces the Acceptance of Five Abstracts and an Invited Oral Presentation at the American Society of Gene and Cell Therapy (ASGCT) 27th Annual Meeting
CAMBRIDGE, Mass., April 22, 2024 (GLOBE NEWSWIRE) -- Generation Bio Co. (Nasdaq:GBIO) a biotechnology company innovating genetic medicines for people...
Generation Bio to Present at the 23rd Annual Needham Virtual Healthcare Conference
Generation Bio to Present at the 23rd Annual Needham Virtual Healthcare Conference
CAMBRIDGE, Mass., April 02, 2024 (GLOBE NEWSWIRE) -- Generation Bio Co. (Nasdaq:GBIO) a biotechnology company innovating genetic medicines for people...
Commit To Buy Generation Bio At $2.50, Earn 39.3% Annualized Using Options
GBIO Stock Earnings: Generation Bio Misses EPS, Beats Revenue for Q4 2023
GBIO stock results show that Generation Bio missed analyst estimates for earnings per share but beat on revenue for the fourth quarter of 2023.
GBIO Stock Earnings: Generation Bio Misses EPS, Beats Revenue for Q4 2023
InvestorPlace - Stock Market News, Stock Advice & Trading Tips Generation Bio (NASDAQ:GBIO) just reported results for the fourth quarter of 20...
Generation Bio Reports Business Highlights and Fourth Quarter and Full Year 2023 Financial Results
Generation Bio Reports Business Highlights and Fourth Quarter and Full Year 2023 Financial Results
- Company is leveraging proprietary cell-targeted lipid nanoparticle delivery to develop wholly-owned in vivo program for sickle cell disease and beta-thalassemia
Generation Bio to Present at the 2024 TD Cowen Health Care Conference
Generation Bio to Present at the 2024 TD Cowen Health Care Conference
CAMBRIDGE, Mass., Feb. 27, 2024 (GLOBE NEWSWIRE) -- Generation Bio Co. (Nasdaq:GBIO) a biotechnology company innovating genetic medicines for people living with rare and prevalent diseases, announced that Geoff McDonough, M.D., president and chief executive officer, will present at the 2024 TD Cowen Health Care Conference on Tuesday, March 5, 2024 at 9:10 a.m. ET in Boston.
Generation Bio to Present at the 42nd Annual J.P. Morgan Healthcare Conference
Generation Bio to Present at the 42nd Annual J.P. Morgan Healthcare Conference
CAMBRIDGE, Mass., Jan. 03, 2024 (GLOBE NEWSWIRE) -- Generation Bio Co. (Nasdaq:GBIO) a biotechnology company innovating genetic medicines for people...
Generation Bio Announces Strategic Reorganization to Extend Cash Runway for Development of ctLNP and iqDNA Platforms
Generation Bio Announces Strategic Reorganization to Extend Cash Runway for Development of ctLNP and iqDNA Platforms
Company to invest in highly selective cell-targeted lipid nanoparticle (ctLNP) delivery platform to develop wholly-owned programs for extrahepatic cell...
Generation Bio Reports Business Highlights and Third Quarter 2023 Financial Results
Generation Bio Reports Business Highlights and Third Quarter 2023 Financial Results
- Immune-quiet DNA evades innate immune sensors in both mice and non-human primates addressing a central challenge for non-viral DNA therapeutics ...
Generation Bio Announces Demonstration of Highly Selective T Cell Transduction In Vivo with Cell-Targeted LNP Platform
Generation Bio Announces Demonstration of Highly Selective T Cell Transduction In Vivo with Cell-Targeted LNP Platform
70% of circulating and splenic T cells positive for mRNA expression in humanized mice with less than 8% delivery to off-target immune cells Stealth...
Generation Bio Announces Breakthrough in its Non-Viral Genetic Medicine Platform with Novel “Immune-Quiet” DNA
Generation Bio Announces Breakthrough in its Non-Viral Genetic Medicine Platform with Novel “Immune-Quiet” DNA
– Immune-quiet DNA (iqDNA) is a novel variant of closed-ended DNA (ceDNA) that evades host innate immune detection in both mice and non-human primates...
Generation Bio to Present at the Jefferies Cell & Genetic Medicine Summit
Generation Bio to Present at the Jefferies Cell & Genetic Medicine Summit
CAMBRIDGE, Mass., Sept. 19, 2023 (GLOBE NEWSWIRE) -- Generation Bio Co. (Nasdaq:GBIO), a biotechnology company innovating genetic medicines for people...
(NASDAQ:GBIO)
Generation Bio press release (GBIO): Q2 GAAP EPS of -$0.47.Cash, cash equivalents, and marketable securities were $314.1 million as of June 30, 2023, compared to $279.1 million as...
Generation Bio to Present at the Canaccord Genuity 43rd Annual Growth Conference
Generation Bio to Present at the Canaccord Genuity 43rd Annual Growth Conference
CAMBRIDGE, Mass., Aug. 03, 2023 (GLOBE NEWSWIRE) -- Generation Bio Co. (Nasdaq:GBIO), a biotechnology company innovating genetic medicines for people...
Generation Bio Reports Second Quarter 2023 Financial Results
Second quarter 2023 cash balance of $314.1 million expected to fund operations into 2025
Generation Bio Reports Second Quarter 2023 Financial Results
Second quarter 2023 cash balance of $314.1 million expected to fund operations into 2025...